BIOSTAPRO AB has a total of 16 patent applications. Its first patent ever was published in 1997. It filed its patents most often in EPO (European Patent Office), Sweden and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and machines are WNTRESEARCH AB, REMEGEN LTD and BYONDIS B V.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 4 | |
#2 | Sweden | 3 | |
#3 | United States | 3 | |
#4 | WIPO (World Intellectual Property Organization) | 3 | |
#5 | Australia | 2 | |
#6 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Machines | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Unspecified technologies | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Frykberg Lars | 9 |
#2 | Jacobsson Karin | 7 |
#3 | Guss Bengt | 7 |
#4 | Nilsson Martin | 5 |
#5 | Flock Jan-Ingmar | 4 |
#6 | Lundberg Fredrik | 4 |
#7 | Dai-Qing Li | 3 |
#8 | Lindberg Martin | 2 |
#9 | Ljungh Aasa | 2 |
#10 | Ljungh Asa | 2 |
Publication | Filing date | Title |
---|---|---|
US2009214584A1 | Characterization of novel lpxtg-containing proteins of staphylococcus epidermidis | |
WO03041726A1 | Use of an extracellular adherence protein for the manufacture of an anti-inflammatory drug | |
EP1328542A1 | Von willebrand factor-binding proteins from staphylococci | |
WO0160852A1 | A 52 kDa PROTEIN FROM COAGULASE NEGATIVE STAPHYLOCOCCI AND FRAGMENTS THEREOF | |
CA2309335A1 | Igg-binding protein from staphylococcus and nucleotide sequence encoding this protein | |
EP0922056A1 | New fibrinogen binding protein originating from coagulase-negative staphylococcus |